(NYSEMKT: PTHS) Pelthos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.
Pelthos Therapeutics's earnings in 2025 is -$23,581,284.On average, 5 Wall Street analysts forecast PTHS's earnings for 2025 to be -$52,621,111, with the lowest PTHS earnings forecast at -$57,038,505, and the highest PTHS earnings forecast at -$47,224,899. On average, 5 Wall Street analysts forecast PTHS's earnings for 2026 to be -$15,042,039, with the lowest PTHS earnings forecast at -$34,505,145, and the highest PTHS earnings forecast at -$1,768,121.
In 2027, PTHS is forecast to generate $9,212,598 in earnings, with the lowest earnings forecast at $8,701,297 and the highest earnings forecast at $9,644,295.